Researchers discover blood biomarker for Lou Gehrig's disease, could lead to new treatments

August 6, 2012

Researchers from Brigham and Women's Hospital (BWH) are the first to discover that changes in monocytes (a type of white blood cell) are a biomarker for amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease. This finding also brings the medical community a step closer toward a new treatment for the debilitating neurological disease that affects approximately 30,000 Americans.

The study will be published online in The on August 6, 2012.

In pre-clinical studies involving mice with an ALS , the researchers saw that two months prior to ALS onset, monocytes in the spleen began exhibiting proinflammatory qualities. As disease onset loomed, there was an increase in cell-signaling molecules that directed monocytes to flood the spinal cord. Influx of these inflamed was associated with nerve cell death in the spinal cord.

When the researchers treated the mice with antibodies to modulate the inflammatory monocytes, they found that it led to fewer monocytes entering the spinal cord, diminished nerve cell loss and extended survival.

After having observed these activities in mice, the BWH researchers, working with the Massachusetts General Hospital (MGH) ALS Clinic and research team, found that there were similar monocytes in humans with ALS that also exhibited a disease-specific inflammatory signature.

"People have wondered if the immune system plays a role in like ALS," said Howard Weiner, MD, director of the BWH Multiple Sclerosis Program and senior study author. "The immune system is complicated, and previous immunotherapy trials have not been successful. But now we know what is wrong in the blood, and this opens up new therapeutic targets for ALS and perhaps other diseases in the near future."

Study co-author Merit Cudkowicz, MD, who heads the ALS program at MGH adds, "These findings identify a potential new for developing treatments for people with ALS."

Oleg Butovsky, PhD, BWH Department of Neurology is first study author and lead scientist on the study.

Each year, approximately 5,600 people in the United States are diagnosed with ALS, a disease that affects nerve and muscle functioning, eventually leading to paralysis. The average age at diagnosis is 55 years old and half of those affected live at least three or more years after being diagnosed. Twenty percent live five years or more, and up to 10 percent will live more than ten years.

Explore further: Potential new drug target in Lou Gehrig's disease

More information: Modulating inflammatory monocytes with a unique microRNA signature ameliorates murine ALS, Journal of Clinical Investigation.

Related Stories

Potential new drug target in Lou Gehrig's disease

November 14, 2011
Two proteins conspire to promote a lethal neurological disease, according to a study published online this week in the Journal of Experimental Medicine.

How immune system, inflammation may play role in Lou Gehrig's disease

June 5, 2012
In an early study, UCLA researchers found that the immune cells of patients with amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease, may play a role in damaging the neurons in the spinal cord. ALS is a disease of ...

Mild obesity appears to improve survival in ALS patients

May 11, 2011
Patients with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, may be an exception to the rule that being overweight is a health hazard. In a retrospective study of over 400 ALS patients, Massachusetts ...

Blocking metabolic protein improves movement in animals with amyotrophic lateral sclerosis

January 17, 2012
Turning off a protein that helps cells balance energy increases animal mobility and reduces the death of nerve cells that control movement in animal models of amyotrophic lateral sclerosis (ALS), according to a study in the ...

Recommended for you

Scientists find key to regenerating blood vessels

November 23, 2017
A new study led by researchers at Sanford Burnham Prebys Medical Discovery Institute (SBP) identifies a signaling pathway that is essential for angiogenesis, the growth of new blood vessels from pre-existing vessels. The ...

Researchers find infectious prions in Creutzfeldt-Jakob disease patient skin

November 22, 2017
Creutzfeldt-Jakob disease (CJD)—the human equivalent of mad cow disease—is caused by rogue, misfolded protein aggregates termed prions, which are infectious and cause fatal damages in the patient's brain. CJD patients ...

Surprising roles for muscle in tissue regeneration, study finds

November 22, 2017
A team of researchers at Whitehead has illuminated an important role for different subtypes of muscle cells in orchestrating the process of tissue regeneration. In a paper published in the November 22 issue of Nature, they ...

Study reveals new mechanisms of cell death in neurodegenerative disorders

November 22, 2017
Researchers at King's College London have discovered new mechanisms of cell death, which may be involved in debilitating neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease.

Cinnamon turns up the heat on fat cells

November 21, 2017
New research from the University of Michigan Life Sciences Institute has determined how a common holiday spice—cinnamon—might be enlisted in the fight against obesity.

How rogue immune cells cross the blood-brain barrier to cause multiple sclerosis

November 21, 2017
Drug designers working on therapeutics against multiple sclerosis should focus on blocking two distinct ways rogue immune cells attack healthy neurons, according to a new study in the journal Cell Reports.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.